Jia (Jenny) Liu, Translational Lead of The Kinghorn Cancer Centre, shared a post on LinkedIn:
“Hadassah Sade sharing industry insights from recent achievements on quantitative biomarkers including the AstraZeneca TROP2 quantitative continuous scoring using AI and deep learning as biomarker for DatoDXD in NSCLC.
Multiplexing is key especially to facilitate tumor agnostic indications and to address the equity issue for patients with rare cancers.”
More posts featuring AstraZeneca on OncoDaily.
